AfterRaise/Companies/R1 Therapeutics

R1 Therapeutics

R1 Therapeutics is a clinical-stage biopharmaceutical company. From its funding announcement.

$78M Series ARaised 7 months agoRedwood City, USABiotech & PharmaUSA

In their own words

What R1 Therapeutics says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "clinical-stage biopharmaceutical company". Source

Research and development

Public signal Read from the company's own description of what the funding supports.

Why now

Where R1 Therapeutics is today

R1 Therapeutics announced a Series A round of $78M on 17 March 2026.

Latest round
Series A
Amount
$78M
Announced
17 March 2026
Headquarters
Redwood City, USA
Sector
Biotech & Pharma
Investors
Not stated
Also participating
Not stated
Relevant leadership
Not stated

Momentum AfterRaise intelligence

AfterRaise Score

43
Established
0 funding signals in the last 90 days
Funding recency
9/40
announced within the last year
Round scale
19/25
round size relative to the market
Funding stage
15/20
Series A
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 17 March 2026
    $78M Series A
    Investors not stated in the announcement.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Research programme expansion
  • Scientific team growth
  • Accelerated hiring across functions
  • Repeatable go-to-market build

Opportunities this could create

  • Clinical operations
  • Scientific hiring
  • Scientific advisers
  • Research operations
  • Specialist suppliers

Based on the Biotech & Pharma sector, a Series A round and the priorities the company itself set out. Not a statement of fact.

Early momentum2 connected signals
  • 17 March 2026$78M Series A announced
  • 17 March 2026Stated priority: research and development

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What R1 Therapeutics is open to

Not yet specified

R1 Therapeutics has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with R1 Therapeutics

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at R1 Therapeutics?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: your website, the roles and projects you have open and who leads the team. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector